Michael Stahl
About
Michael Stahl is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Oral Surgery.
According to data from OpenAlex, Michael Stahl has authored 18 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Oral Surgery. Recurrent topics in Michael Stahl's work include Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (7 papers) and Cancer Diagnosis and Treatment (6 papers). Michael Stahl is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (7 papers) and Cancer Diagnosis and Treatment (6 papers). Michael Stahl collaborates with scholars based in Germany, United States and Switzerland. Michael Stahl's co-authors include Salah‐Eddin Al‐Batran, Florian Lordick, Frank Kullmann, Gunnar Folprecht, Albrecht Kretzschmar, Hartmut Link, Axel Hinke, S Daum, H. Wilke and Horst Lindhofer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.
In The Last Decade
Michael Stahl
18 papers receiving 296 citations
Peers
Michael Stahl
Aurelio Matamoros United States
Sam Pyo Hong South Korea
Kiran Kothari India
Samhita Chakraborty United States
Olga L. Bohn United States
Sumika Matsukita Japan
Jessy Delaye France
Irina Babayan United States
Donald L. Sears United States
Daniel M. Girardi Brazil
Citations per year, relative to Michael Stahl Michael Stahl (= 1×)
peers
Aurelio Matamoros
Countries citing papers authored by Michael Stahl
Since
Specialization
Citations
This map shows the geographic impact of Michael Stahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Stahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Stahl more than expected).
Fields of papers citing papers by Michael Stahl
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael Stahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Stahl. The network helps show where Michael Stahl may publish in the future.
Co-authorship network of co-authors of Michael Stahl
This figure shows the co-authorship network connecting the top 25 collaborators of Michael Stahl. A scholar is included among the top collaborators of Michael Stahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Stahl. Michael Stahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Güller, Ulrich, Stefanie Hayoz, Daniel Horber, et al.. (2025). Adjuvant Aspirin Treatment in PIK3CA -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial. Clinical Cancer Research. 31(15). 3142–3149.
2.
Hertz, Daniel L., Markus Joerger, Yung‐Jue Bang, et al.. (2024). Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. European Journal of Cancer. 202. 114024–114024.
3.
Heinemann, Volker, Laura Fischer, Frank Gieseler, et al.. (2023). SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group. Annals of Oncology. 34. S164–S164.
4.
Mileshkin, Linda, Tilmann Bochtler, Chantal Pauli, et al.. (2023). LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP). Annals of Oncology. 34. S1254–S1255.
5.
Lorenzen, Sylvie, Peter Thuss‐Patience, Claudia Pauligk, et al.. (2022). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. European Journal of Cancer. 165. 48–57.
6.
Folprecht, Gunnar, Alexander Stein, Michael Stahl, et al.. (2020). Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. British Journal of Cancer. 124(4). 721–727.
7.
Lorenzen, Sylvie, Peter Thuss‐Patience, Claudia Pauligk, et al.. (2020). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.. Journal of Clinical Oncology. 38(15_suppl). 4514–4514.
8.
Lorenzen, Sylvie, Michael Stahl, Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, & Florian Lordick. (2019). Influence of Taxanes on Treatment Sequence in Gastric Cancer. Oncology Research and Treatment. 43(1-2). 42–47.
9.
Krämer, Alwin, Alexander Stein, Michael Stahl, et al.. (2019). Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. Journal of Clinical Oncology. 37(15_suppl). 4120–4120.
10.
Knödler, Maren, Volker Kunzmann, Jörg Trojan, et al.. (2018). Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. British Journal of Cancer. 119(3). 296–302.
11.
Lorenzen, Sylvie, Peter Thuss‐Patience, Claudia Pauligk, et al.. (2018). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study.. Journal of Clinical Oncology. 36(15_suppl). TPS4132–TPS4132.
12.
Haas, Michael, Dirk Waldschmidt, Michael Stahl, et al.. (2018). Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT). Annals of Oncology. 29. viii243–viii243.
13.
Jordan, Karin, Tim Luetkens, C. Gog, et al.. (2016). Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108. European Journal of Cancer. 63. 127–134.
14.
Hainsworth, John D., Gedske Daugaard, Thierry Lesimple, et al.. (2015). Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer. 121(10). 1654–1661.
15.
Folprecht, Gunnar, et al.. (2009). Phase II Trial of Capecitabine and Oxaliplatin in Patients with Adeno- and Undifferentiated Carcinoma of Unknown Primary. Oncology Research and Treatment. 32(4). 162–166.
16.
Link, Hartmut, C.-H. Köhne, Michael Stahl, et al.. (2008). Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. British Journal of Cancer. 100(1). 44–49.
17.
Stamatis, Georgios, et al.. (2004). Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Clinical Drug Investigation. 24(10). 611–618.
18.
Wilke, H., P. Preusser, Michael Stahl, et al.. (1991). Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 29(1). 83–84.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Aurelio Matamoros Breakdown of academic impact, for papers by Sam Pyo Hong Breakdown of academic impact, for papers by Kiran Kothari Breakdown of academic impact, for papers by Samhita Chakraborty Breakdown of academic impact, for papers by Olga L. Bohn Breakdown of academic impact, for papers by Sumika Matsukita Breakdown of academic impact, for papers by Jessy Delaye Breakdown of academic impact, for papers by Irina Babayan Breakdown of academic impact, for papers by Donald L. Sears Breakdown of academic impact, for papers by Daniel M. Girardi